Portal de Periódicos da CAPES

Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis B

2012; Mary Ann Liebert, Inc.; Volume: 32; Issue: 6 Linguagem: Inglês

10.1089/jir.2011.0109

1557-7465

Juan Wang, Yanjun Cai, Huifan Ji, Junyan Feng, Desalegn Admassu Ayana, Junqi Niu, Yanfang Jiang,

Eosinophilic Esophagitis

This aim of this study was to assess the potential role of IL-33 in the pathogenic process of chronic hepatitis B (CHB). The levels of serum IL-33 and soluble ST2 (sST2) in CHB patients and healthy controls (HC) were determined using enzyme-linked-immunosorbent serologic assay, and the Th1 (IFN-γ, TNF-α, IL-2) and Th2 (IL-4, IL-6, IL-10) cytokines by cytometric bead array. It was found that the levels of serum IL-33 in CHB patients were significantly higher than that of HC at the base line, but decreased after treatment with adefovir dipivoxil for 12 weeks. The levels of serum sST2, as a decoy receptor of IL-33, were significantly higher in CHB patients than the HC. There was no correlation between the levels of serum sST2 and IL-33. The concentrations of serum Th1 (IFN-γ, IL-2) and Th2 (IL-6, IL-10) cytokines in CHB patients significantly increased after treatment compared to the baseline. These results suggest that IL-33 is involved in the pathogenesis of CHB and that adefovir dipivoxil therapy can attenuate the production of IL-33 in patients with CHB.